Bacterial Lung Infections in Cystic Fibrosis Patients An Update
Bacterial Lung Infections in Cystic Fibrosis Patients An Update
复制标题
DOI：
10.1097/inf.0000000000000347
复制
发表时间：
2014-06-01
影响因子：
3.6
通讯作者：
de Martino, Maurizio
中科院分区：
文献类型：
--
作者：
Chiappini, Elena;Taccetti, Giovanni;de Martino, Maurizio
氧化无色杆菌（Ax）可能在肺部疾病中发挥重要作用，因为慢性感染与临床状况恶化有关。2，3，7 CF中心之间的患病率差异很大，但成人患者的患病率通常较高。最近在无色杆菌属中描述了几个新的物种，其中Ax占感染的42%。目前，每个物种的毒力都需要定义。美罗培南、哌拉西林-他唑巴坦和甲氧苄啶-磺胺甲恶唑通常在未经化疗的Ax菌株中具有活性，而来自慢性感染患者的菌株对抗生素具有高度耐药性。最近的一项回顾性研究描述了早期吸入抗生素治疗预防或延迟慢性Ax感染的可能性。[7]关于慢性维持治疗，目前还没有达成共识。
Achromobacter xyloxidans(Ax) may play an important role in lung disease as chronic infection has been associated to a deterioration of clinical conditions. 2, 3, 7 The prevalence rates vary considerably among CF centers but are usually higher in adult patients. Several novel species have been recently described in the Achromobacter genus, where Ax accounts for 42% of infections. At present, the virulence of every single species needs to be defined. Meropenem, piperacillin-tazobactam and trimethoprim-sulfamethoxazole are usually active in chemotherapy-naïve Ax strains, whereas isolates from patients chronically infected are highly resistant to antibiotics. A retrospective study recently described the possibility of preventing or delaying chronic Ax infections with early inhaled antibiotic treatment. 7 No consensus exists regarding chronic maintenance therapy.